Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
PolyPid ( (PYPD) ) has issued an announcement.
On May 12, 2025, PolyPid Ltd.’s Board of Directors approved an increase in the number of ordinary shares reserved for issuance under its Amended and Restated 2012 Share Option Plan by 1,200,000 shares, raising the total from 2,312,403 to 3,512,403 shares. This strategic move is aimed at incentivizing employees and stakeholders by providing them with additional options, potentially enhancing their engagement and interest in the company’s success.
The most recent analyst rating on (PYPD) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on PolyPid stock, see the PYPD Stock Forecast page.
Spark’s Take on PYPD Stock
According to Spark, TipRanks’ AI Analyst, PYPD is a Neutral.
PolyPid’s score reflects significant financial challenges, including consistent losses and negative equity. While the company’s clinical advancements and financing efforts are promising, they are not sufficient to offset the financial risks. The stock exhibits neutral technical indicators and an unattractive valuation, limiting its appeal to investors.
To see Spark’s full report on PYPD stock, click here.
More about PolyPid
PolyPid Ltd. operates in the biotechnology industry, focusing on the development of innovative therapies to address unmet medical needs. The company is known for its proprietary PLEX technology, which is designed to deliver drugs in a controlled and sustained manner to improve treatment outcomes.
Average Trading Volume: 21,557
Technical Sentiment Signal: Sell
Current Market Cap: $28.43M
See more insights into PYPD stock on TipRanks’ Stock Analysis page.